Related Experiment Videos

Decrease in lymphokine-activated killer sensitivity of a human renal-cell carcinoma cell line after cytokine

M Yanase1, T Tsukamoto, Y Kumamoto

  • 1Department of Urology, Sapporo Medical University, Japan.

Insights

Cytokine treatment decreased the sensitivity of renal-cell carcinoma cells to lymphokine-activated killer (LAK) cells. This reduction in LAK sensitivity was linked to protein synthesis, suggesting a novel therapeutic target.

Area of Science:

  • Immunology
  • Oncology
  • Cell Biology

Background:

  • Cytokine therapy can modulate tumor cell sensitivity to immune effector cells like lymphokine-activated killer (LAK) cells.
  • The specific mechanisms underlying these modulations vary significantly between different tumor cell lines.

Purpose of the Study:

  • To investigate the impact of cytokine treatment on the LAK cell sensitivity of a human renal-cell carcinoma cell line (SMKT-R-3).
  • To elucidate the molecular mechanisms responsible for altered LAK sensitivity following cytokine exposure.

Main Methods:

  • Treatment of SMKT-R-3 cells with a combination of interferon gamma (IFN-γ) and tumor necrosis factor (TNF).
  • Assessment of LAK cell sensitivity and expression of intercellular adhesion molecule-1 (ICAM-1).
  • Evaluation of LAK sensitivity in the presence of actinomycin D, a protein synthesis inhibitor.

Main Results:

  • Cytokine treatment (IFN-γ and TNF) decreased the LAK sensitivity of SMKT-R-3 cells.
  • Cytokine treatment led to increased expression of ICAM-1 on the tumor cell surface.
  • Inhibition of protein synthesis with actinomycin D restored LAK sensitivity to baseline levels.

Conclusions:

  • The observed decrease in LAK sensitivity of renal-cell carcinoma cells by cytokine treatment is mediated by protein synthesis.
  • These findings suggest that protein synthesis occurring during LAK cell interaction with tumor cells plays a crucial role in modulating immune response.

Related Concept Videos